Protective effects of high-molecular weight Polyethylene Glycol (PEG) in human lung endothelial cell barrier regulation

Role of actin cytoskeletal rearrangement

Eddie T. Chiang, Sara M. Camp, Steven M. Dudek, Mary E. Brown, Peter V. Usatyuk, Olga Zaborina, John C. Alverdy, Joe GN Garcia

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Acute lung injury represents the result of multiple pathways initiated by local or systemic insults and is characterized by profound vascular permeability, pulmonary edema, and life-threatening respiratory failure. Permeability-reducing therapies are of potential clinical utility but are currently unavailable. We hypothesized that polyethylene glycol (PEG) compounds, inert and non-toxic polymers that serve as a surrogate mucin lining in intestinal epithelium, may attenuate agonist-mediated lung endothelial cell (EC) barrier dysfunction. High molecular weight PEG (PEG15-20) produced rapid, dose-dependent increases in transendothelial electrical resistance (TER) in human lung endothelium cultured on gold microelectrodes, reflecting increased paracellular integrity. The maximal effective concentration of 8% PEG induced a sustained 125% increase in TER (40 h), results similar to barrier-enhancing agonists such as sphingosine 1-phosphate (40% increase in TER). Maximal PEG barrier enhancement was achieved at 45-60 min and PEG effectively reversed both thrombin- and LPS-induced EC barrier dysfunction. Consistent with the increase in TER, immunofluorescent studies demonstrated that PEG produced significant cytoskeletal rearrangement with formation of well-defined cortical actin rings and lamellipodia containing the actin-binding proteins, cortactin and MLCK, known participants in cell-matrix and cell-cell junctional adhesion. Finally, PEG challenge induced rapid alterations in levels of MAP kinase and MLC phosphorylation. In summary, PEG joins a number of EC barrier-regulatory agents which rapidly activate barrier-enhancing signal transduction pathways which target the cytoskeleton and provides a potential therapeutic strategy in inflammatory lung injury.

Original languageEnglish (US)
Pages (from-to)174-186
Number of pages13
JournalMicrovascular Research
Volume77
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Endothelial cells
Actins
Endothelial Cells
Molecular Weight
Molecular weight
Lung
Acoustic impedance
Electric Impedance
Cortactin
Microfilament Proteins
Signal transduction
Phosphorylation
Pseudopodia
Acute Lung Injury
Microelectrodes
Cell adhesion
Capillary Permeability
Lung Injury
Mucins
Pulmonary Edema

Keywords

  • Barrier function
  • Endothelium
  • LPS
  • PEG
  • Thrombin

ASJC Scopus subject areas

  • Biochemistry
  • Cardiology and Cardiovascular Medicine
  • Cell Biology

Cite this

Protective effects of high-molecular weight Polyethylene Glycol (PEG) in human lung endothelial cell barrier regulation : Role of actin cytoskeletal rearrangement. / Chiang, Eddie T.; Camp, Sara M.; Dudek, Steven M.; Brown, Mary E.; Usatyuk, Peter V.; Zaborina, Olga; Alverdy, John C.; Garcia, Joe GN.

In: Microvascular Research, Vol. 77, No. 2, 03.2009, p. 174-186.

Research output: Contribution to journalArticle

Chiang, Eddie T. ; Camp, Sara M. ; Dudek, Steven M. ; Brown, Mary E. ; Usatyuk, Peter V. ; Zaborina, Olga ; Alverdy, John C. ; Garcia, Joe GN. / Protective effects of high-molecular weight Polyethylene Glycol (PEG) in human lung endothelial cell barrier regulation : Role of actin cytoskeletal rearrangement. In: Microvascular Research. 2009 ; Vol. 77, No. 2. pp. 174-186.
@article{3781b93d444f4f82a18c03cf949f0a19,
title = "Protective effects of high-molecular weight Polyethylene Glycol (PEG) in human lung endothelial cell barrier regulation: Role of actin cytoskeletal rearrangement",
abstract = "Acute lung injury represents the result of multiple pathways initiated by local or systemic insults and is characterized by profound vascular permeability, pulmonary edema, and life-threatening respiratory failure. Permeability-reducing therapies are of potential clinical utility but are currently unavailable. We hypothesized that polyethylene glycol (PEG) compounds, inert and non-toxic polymers that serve as a surrogate mucin lining in intestinal epithelium, may attenuate agonist-mediated lung endothelial cell (EC) barrier dysfunction. High molecular weight PEG (PEG15-20) produced rapid, dose-dependent increases in transendothelial electrical resistance (TER) in human lung endothelium cultured on gold microelectrodes, reflecting increased paracellular integrity. The maximal effective concentration of 8{\%} PEG induced a sustained 125{\%} increase in TER (40 h), results similar to barrier-enhancing agonists such as sphingosine 1-phosphate (40{\%} increase in TER). Maximal PEG barrier enhancement was achieved at 45-60 min and PEG effectively reversed both thrombin- and LPS-induced EC barrier dysfunction. Consistent with the increase in TER, immunofluorescent studies demonstrated that PEG produced significant cytoskeletal rearrangement with formation of well-defined cortical actin rings and lamellipodia containing the actin-binding proteins, cortactin and MLCK, known participants in cell-matrix and cell-cell junctional adhesion. Finally, PEG challenge induced rapid alterations in levels of MAP kinase and MLC phosphorylation. In summary, PEG joins a number of EC barrier-regulatory agents which rapidly activate barrier-enhancing signal transduction pathways which target the cytoskeleton and provides a potential therapeutic strategy in inflammatory lung injury.",
keywords = "Barrier function, Endothelium, LPS, PEG, Thrombin",
author = "Chiang, {Eddie T.} and Camp, {Sara M.} and Dudek, {Steven M.} and Brown, {Mary E.} and Usatyuk, {Peter V.} and Olga Zaborina and Alverdy, {John C.} and Garcia, {Joe GN}",
year = "2009",
month = "3",
doi = "10.1016/j.mvr.2008.11.007",
language = "English (US)",
volume = "77",
pages = "174--186",
journal = "Microvascular Research",
issn = "0026-2862",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Protective effects of high-molecular weight Polyethylene Glycol (PEG) in human lung endothelial cell barrier regulation

T2 - Role of actin cytoskeletal rearrangement

AU - Chiang, Eddie T.

AU - Camp, Sara M.

AU - Dudek, Steven M.

AU - Brown, Mary E.

AU - Usatyuk, Peter V.

AU - Zaborina, Olga

AU - Alverdy, John C.

AU - Garcia, Joe GN

PY - 2009/3

Y1 - 2009/3

N2 - Acute lung injury represents the result of multiple pathways initiated by local or systemic insults and is characterized by profound vascular permeability, pulmonary edema, and life-threatening respiratory failure. Permeability-reducing therapies are of potential clinical utility but are currently unavailable. We hypothesized that polyethylene glycol (PEG) compounds, inert and non-toxic polymers that serve as a surrogate mucin lining in intestinal epithelium, may attenuate agonist-mediated lung endothelial cell (EC) barrier dysfunction. High molecular weight PEG (PEG15-20) produced rapid, dose-dependent increases in transendothelial electrical resistance (TER) in human lung endothelium cultured on gold microelectrodes, reflecting increased paracellular integrity. The maximal effective concentration of 8% PEG induced a sustained 125% increase in TER (40 h), results similar to barrier-enhancing agonists such as sphingosine 1-phosphate (40% increase in TER). Maximal PEG barrier enhancement was achieved at 45-60 min and PEG effectively reversed both thrombin- and LPS-induced EC barrier dysfunction. Consistent with the increase in TER, immunofluorescent studies demonstrated that PEG produced significant cytoskeletal rearrangement with formation of well-defined cortical actin rings and lamellipodia containing the actin-binding proteins, cortactin and MLCK, known participants in cell-matrix and cell-cell junctional adhesion. Finally, PEG challenge induced rapid alterations in levels of MAP kinase and MLC phosphorylation. In summary, PEG joins a number of EC barrier-regulatory agents which rapidly activate barrier-enhancing signal transduction pathways which target the cytoskeleton and provides a potential therapeutic strategy in inflammatory lung injury.

AB - Acute lung injury represents the result of multiple pathways initiated by local or systemic insults and is characterized by profound vascular permeability, pulmonary edema, and life-threatening respiratory failure. Permeability-reducing therapies are of potential clinical utility but are currently unavailable. We hypothesized that polyethylene glycol (PEG) compounds, inert and non-toxic polymers that serve as a surrogate mucin lining in intestinal epithelium, may attenuate agonist-mediated lung endothelial cell (EC) barrier dysfunction. High molecular weight PEG (PEG15-20) produced rapid, dose-dependent increases in transendothelial electrical resistance (TER) in human lung endothelium cultured on gold microelectrodes, reflecting increased paracellular integrity. The maximal effective concentration of 8% PEG induced a sustained 125% increase in TER (40 h), results similar to barrier-enhancing agonists such as sphingosine 1-phosphate (40% increase in TER). Maximal PEG barrier enhancement was achieved at 45-60 min and PEG effectively reversed both thrombin- and LPS-induced EC barrier dysfunction. Consistent with the increase in TER, immunofluorescent studies demonstrated that PEG produced significant cytoskeletal rearrangement with formation of well-defined cortical actin rings and lamellipodia containing the actin-binding proteins, cortactin and MLCK, known participants in cell-matrix and cell-cell junctional adhesion. Finally, PEG challenge induced rapid alterations in levels of MAP kinase and MLC phosphorylation. In summary, PEG joins a number of EC barrier-regulatory agents which rapidly activate barrier-enhancing signal transduction pathways which target the cytoskeleton and provides a potential therapeutic strategy in inflammatory lung injury.

KW - Barrier function

KW - Endothelium

KW - LPS

KW - PEG

KW - Thrombin

UR - http://www.scopus.com/inward/record.url?scp=60449096746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60449096746&partnerID=8YFLogxK

U2 - 10.1016/j.mvr.2008.11.007

DO - 10.1016/j.mvr.2008.11.007

M3 - Article

VL - 77

SP - 174

EP - 186

JO - Microvascular Research

JF - Microvascular Research

SN - 0026-2862

IS - 2

ER -